Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

In this work, the characterization and diversity of 347 compounds from betel nut ( L.) were analyzed for the first time. The dataset of compounds from betel nut (BNC) was compared to compounds from food. They were analyzed in terms of physicochemical properties, scaffold diversity, molecular fingerprints, and global diversity. Approximately 48% of compounds in the BNC confirm Lipinski's and Pfizer's rules. The pharmacological and toxicological properties of edible betel nut were evaluated based on their composition. This work applied the research methods of cheminformatics to food science, and it provided theoretical support and data for betel nut pharmacological research, development of betel nut-related novel medication, and healthy products.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739985PMC
http://dx.doi.org/10.1021/acsomega.4c09386DOI Listing

Publication Analysis

Top Keywords

betel nut
20
compounds betel
12
physicochemical properties
8
betel
6
compounds
5
nut
5
cheminformatics exploration
4
exploration structural
4
structural physicochemical
4
properties molecular
4

Similar Publications

: While there are known high rates of tobacco and betel (areca) nut use in the U.S.-Affiliated Pacific Islands (USAPI), there have been limited efforts at preventing the initiation of tobacco and betel nut among those living in the region, particularly, adolescents.

View Article and Find Full Text PDF

Prevalence of Oral Potentially Malignant Disorders in Smokeless Tobacco Users With or Without Areca Nut: A Meta-Analysis.

J Oral Pathol Med

September 2025

Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, Arabian Gulf University, Manama, Bahrain.

Background: Smokeless tobacco (SLT) use is a major global risk factor for oral potentially malignant disorders (OPMDs). However, the differential impact of SLT product composition, particularly tobacco-only versus combined tobacco-areca nut products, on OPMD prevalence remains inadequately characterized.

Objective: To compare the pooled prevalence of OPMDs between users of tobacco-only SLT and users of SLT containing both tobacco and areca nut.

View Article and Find Full Text PDF

YY1 lactylation promotes fibroblast senescence by targeting the PU.1-BTG2 axis to promote oral submucous fibrosis.

Chem Biol Interact

August 2025

Department of Oral and Maxillofacial Surgery, Center of Stomatology, Xiangya Hospital, Central South University, Changsha, China; Department of Oral Medicine, Center of Stomatology, Xiangya Hospital, Central South University, Changsha, China; Institute of Oral Precancerous Lesions, Central South Uni

Oral submucous fibrosis (OSF) is a chronic fibrotic disease common in Asia-Pacific regions and strongly linked to long-term areca nut chewing. Fibroblast senescence is known to contribute to tissue fibrosis, but the molecular mechanisms behind it remain unclear. In this study, we explored how arecoline, a key component of areca nut, influences fibroblast behavior.

View Article and Find Full Text PDF

The Areca Nut and Oral Submucosal Fibrosis: A Narrative Review.

Dent J (Basel)

August 2025

College of Dentistry, University of Saskatchewan, 105 Wiggins Road, Saskatoon, SK S7N 5E4, Canada.

The areca nut (AN) is chewed by approximately 600 million people worldwide. Among AN chewers, ~5% develop oral submucosal fibrosis (OSF), a progressive fibrotic disorder of the oral cavity. OSF is characterized by subepithelial fibrosis and mucosal rigidity, leading to restricted mouth opening, difficulty in mastication, deglutition, and speech.

View Article and Find Full Text PDF

Background: Tobacco use is the largest preventable risk of non-communicable diseases (NCDs). Moreover, tobacco use interferes with glycaemic control, and there is a proven link between smoking and diabetes complications.

Aim: This cross-sectional study investigates the prevalence of tobacco use and the effect of advice about quitting and its impact at one-month and one-year follow-ups in outpatient type 2 diabetics.

View Article and Find Full Text PDF